- Press releases
- Country: United States
GPN Vaccines Closes Fully Subscribed US$10 Million Private Placement to Advance Gamma-PN™, a Potentially First-in-Class Serotype-Independent Pneumococcal Vaccine
Proceeds to support Phase 2-enabling activities for Gamma-PN, including cGMP manufacturing, expansion of the Company's OPA-testing capabilities and planned submission of an IND to the FDA NEW YORK and ADELAIDE, Australia, Nov. 2, 2026 /PRNewswire/ -- GPN Vaccines, Inc., a clinical-stage...